Can you take Wegovy if you have kidney disease?

Step 1: How kidney function is assessed before Wegovy is prescribed

The first thing any prescriber will want to know is where your kidney function currently sits. In clinical practice this is measured by eGFR (estimated glomerular filtration rate), derived from a blood test. The Wegovy Summary of Product Characteristics (the document that defines how the medicine can be used) does not list kidney disease as an absolute contraindication. What it does note is that data in people with severe renal impairment (eGFR below 15 ml/min/1.73m²) or end-stage renal disease are very limited, and use in this group is generally not recommended.

For mild-to-moderate chronic kidney disease (roughly eGFR 30–89), the picture is less restrictive. The prescriber looks at the whole clinical picture: what caused the kidney disease, what other medicines you take, your blood pressure, and whether you have type 2 diabetes alongside it. A coexisting diabetes diagnosis is common in people with kidney disease, and that context matters for treatment choices.

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician who reviews your answers and medical history the same day. If kidney disease is in the picture, they will factor in your most recent test results and, where appropriate, recommend you discuss the decision with your GP or renal specialist before proceeding.

Step 2: The dehydration risk, why GI side effects matter more when your kidneys are compromised

Semaglutide's most common side effects are gastrointestinal: nausea, vomiting, diarrhoea and, less often, constipation. For most people these are mild and settle over the first few weeks of treatment or after a dose increase. For someone with reduced kidney function, however, persistent vomiting or diarrhoea carries a specific risk: dehydration, which can cause a sharp, sometimes dangerous drop in kidney performance, clinicians call this acute kidney injury on chronic kidney disease.

The NHS patient information on semaglutide advises staying well hydrated and contacting a healthcare professional promptly if you cannot keep fluids down. That advice applies to everyone, but it applies with more urgency if your kidneys are already working harder than they should be. The slow titration schedule that Wegovy uses (starting low and stepping up gradually) is partly designed to reduce the severity of these GI effects, which is one reason the starting dose is not the treatment dose.

If you are unsure whether a side effect warrants a call to your GP or a 111 assessment, our FAQs cover the signals to watch for, and our aftercare team is available seven days a week.

Step 3: What the evidence says about semaglutide and kidney outcomes

This is where the picture gets more optimistic, though careful framing matters. The FLOW trial (semaglutide 1.0mg, the Ozempic dose, in adults with type 2 diabetes and chronic kidney disease) reported that semaglutide reduced the risk of kidney disease progression and cardiovascular death compared with placebo. Those findings are promising and have influenced clinical thinking, but they used a lower dose than Wegovy's 2.4mg maintenance, and the population studied had both diabetes and CKD together.

Extrapolating that data to people using Wegovy for weight management alone, or to those with CKD from other causes, requires caution. NICE's appraisal of semaglutide for weight management (NICE TA875) does not base its recommendations on kidney outcomes; it focuses on weight and comorbidity management. The research is genuinely encouraging, but it does not override individual clinical assessment. Your prescriber or renal specialist is best placed to weigh it against your specific situation, and if you want to understand how eligibility is affected in practice, our page answering whether you can take Wegovy with kidney disease sets out the key considerations in detail. Semaglutide and kidney disease is a topic our content covers in more detail if you want to read further.

Step 4: Getting a decision, NHS route, private route, and what to expect

On the NHS, Wegovy is available through specialist weight management services under NICE TA875, with strict eligibility criteria and, in many areas, significant waiting times. If your kidney disease is managed by a renal consultant, any weight-loss medicine would ideally be discussed with them before you start, not because the two teams conflict, but because co-ordinated care produces better outcomes.

The private route removes the waiting list but not the clinical rigour. If you start a consultation with us and your answers indicate significant kidney impairment, our prescriber will be transparent with you: they may ask for evidence of recent kidney function tests, suggest you speak with your GP or nephrologist first, or decline to prescribe if they judge it unsuitable. That is how responsible prescribing works. Browse our weight-loss treatments page to see what a consultation involves, or read about Wegovy and chronic kidney disease for a deeper look at how different CKD stages affect the decision.

People sometimes ask whether conditions beyond kidney disease affect eligibility too. Epilepsy is one example worth reading about separately, our page on Wegovy and epilepsy covers what the guidance says there. And if you are exploring weight management more broadly before committing to a specific medicine, the weight loss overview is a good place to start. Worth checking: our clinical team page explains who reviews your consultation and what their qualifications are.